Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.
暂无分享,去创建一个
H. Levin | E. Klein | P. Clark | R. Dreicer | D. Peereboom | Sarah B. Clark | S. B. Clark
[1] H. Levin,et al. Intermediate‐Term Outcome with Radical Prostatectomy for Localized Prostate Cancer: The Cleveland Clinic Experience , 2001 .
[2] P. Troncoso,et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] W. Catalona,et al. Contemporary results of anatomic radical prostatectomy , 1999, CA: a cancer journal for clinicians.
[4] W. Catalona,et al. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. , 1998, The Journal of urology.
[5] H. Levin,et al. Initial dissection of the lateral fascia reduces the positive margin rate in radical prostatectomy. , 1998, Urology.
[6] R. Millikan,et al. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[7] A W Partin,et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.
[8] A. Partin,et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. , 1997, The Urologic clinics of North America.
[9] H. Levin,et al. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. , 1997, The cancer journal from Scientific American.
[10] H. Levin,et al. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. , 1996, Urology.
[11] S. Mani,et al. Is "off-protocol" chemotherapy for androgen-independent carcinoma of prostate warranted? , 1996, Hematology/oncology clinics of North America.
[12] D. Wood,et al. Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockage in Clinical Stage B2 (T2bNxM0) Prostate Cancer , 1995 .
[13] L. Baert,et al. Morphologic and lmmunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies , 1994, Cancer.
[14] B. Redman,et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] C. Logothetis,et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] K. Tew,et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] E. Klein,et al. Acute complications after radical retropubic prostatectomy , 2000 .